REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

World News: . []

ROCKVILLE Md Sept 20 2017 GLOBE NEWSWIRE -- REGENXBIO Inc NasdaqRGNX a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platfo rm, tod...

More news and information about REGENXBIO Inc.

Published By:

Globe Newswire: 12:00 GMT Wednesday 20th September 2017

Published: .

Search for other references to "regenxbio" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us